Abstract: ABT-737 is a potent, small-molecule BH3-mimetic that selectively targets and inhibits anti-apoptotic BCL-2 family proteins, specifically BCL-2, BCL-XL, and BCL-W. Originally developed as an anti-cancer agent to trigger apoptosis in malignant cells, ABT-737 has emerged as a highly effective senolytic compound capable of selectively clearing senescent cells. By disrupting the delicate balance of upregulated pro- and anti-apoptotic proteins in senescent cells, ABT-737 reactivates the intrinsic mitochondrial apoptotic pathway. Despite its robust in vitro and in vivo efficacy in models of aging, lung fibrosis, and various cancers, the clinical translation of ABT-737 has been hindered by its lack of oral bioavailability and dose-limiting on-target toxicity, most notably thrombocytopenia. This review synthesizes current literature on ABT-737, detailing its pharmacological activity, molecular mechanism of action, structure-activity relationships, current limitations, and future perspectives in senolytic and oncological therapies.
1. Introduction
Cellular senescence is a state of irreversible cell cycle arrest induced by various stressors, including telomere shortening, oncogenic activation, oxidative stress, and DNA damage [1]. While transient senescence plays a beneficial role in wound healing and tumor suppression, the chronic accumulation of senescent cells contributes significantly to tissue dysfunction and age-related diseases such as pulmonary fibrosis, atherosclerosis, and osteoarthritis [1]. Senescent cells remain viable and resist apoptosis despite high levels of metabolic activity and DNA damage, largely due to the upregulation of anti-apoptotic BCL-2 family proteins [1].
ABT-737 is a pioneering small-molecule inhibitor designed to mimic the BH3 domain of pro-apoptotic proteins. It functions as a targeted inhibitor of specific anti-apoptotic BCL-2 family members [3][8]. By neutralizing these survival proteins, ABT-737 has demonstrated profound potential not only as an anti-cancer therapeutic but also as a senolytic agent—a class of drugs that selectively induce apoptosis in senescent cells to rejuvenate tissue function and delay age-related pathologies [1].
2. Pharmacological Activity
As a senolytic agent, ABT-737 exhibits robust pharmacological activity by selectively clearing senescent cells without negatively affecting normal, healthy cells. In vitro studies demonstrate that ABT-737 can eliminate more than 65% of senescent cells, including human lung fibroblasts (IMR-90, WI-38) and murine embryonic fibroblasts (MEFs) [1]. In vivo, ABT-737 treatment significantly reduces the expression of BCL-XL and BCL-W in irradiation-induced lung fibrosis mouse models, thereby decreasing the senescent cell burden and ameliorating pulmonary fibrosis [1]. Furthermore, in p14Arf-induced transgenic mice, ABT-737 successfully clears senescent epidermal cells, which promotes hair follicle stem cell proliferation and repopulates the stem cell compartment [1].
Beyond senolytics, ABT-737 has substantial anti-tumor activity. It effectively induces apoptosis in various malignancies, including small cell lung cancer (SCLC), glioblastoma, and hematological cancers such as multiple myeloma and Human T-cell Leukemia Virus type 1 (HTLV-1)-associated Adult T-cell Leukemia/Lymphoma (ATLL) [3][4][6]. Additionally, at low concentrations, ABT-737 has shown neuroprotective properties by binding to and inactivating the neurotoxic truncated protein ΔN-Bcl-xL, thereby protecting mitochondrial function and enhancing neuronal viability against excitotoxic insults [7].
3. Molecular Mechanism of Action
The molecular mechanism of ABT-737 relies on its ability to activate the intrinsic, mitochondrial-mediated apoptotic pathway. In senescent and malignant cells, survival is maintained by an upregulated, yet fragile, balance between anti-apoptotic proteins (BCL-2, BCL-XL, BCL-W) and pro-apoptotic proteins (such as BIM, PUMA, BAX, and BAK) [1][8]. ABT-737 acts as a BH3-mimetic, competitively binding to the hydrophobic groove of BCL-2, BCL-XL, and BCL-W [3][4].
By occupying this groove, ABT-737 displaces sequestered pro-apoptotic BH3-only proteins. The liberated pro-apoptotic proteins subsequently activate the effector proteins BAX and BAK. This activation leads to BAX/BAK oligomerization and translocation to the mitochondrial outer membrane, causing mitochondrial outer membrane permeabilization (MOMP) [3][9]. MOMP results in the release of cytochrome c into the cytosol, which triggers the activation of caspase-9 and subsequently the executioner caspase-3, leading to PARP cleavage and irreversible cellular apoptosis [4][5]. Notably, ABT-737 can induce apoptosis bypassing extrinsic death receptors, directly engaging the mitochondrial apoptotic machinery [9].
4. Structure-Activity Relationship (SAR)
The discovery and optimization of ABT-737 were achieved through a technique known as "SAR by NMR" (Structure-Activity Relationship by Nuclear Magnetic Resonance). This fragment-based drug discovery approach involved screening chemical libraries to identify small molecular fragments that bound to distinct sites within the hydrophobic groove of the BCL-XL protein [3]. By chemically linking these proximal fragments, researchers developed ABT-737, a lead compound that binds with exceptionally high affinity (Ki < 1 nM) to BCL-XL, as well as to the structurally similar BCL-2 and BCL-W proteins [3][8].
However, the structural specificity of ABT-737 also dictates its limitations. The anti-apoptotic proteins MCL-1, BCL-B, and BCL2A1 possess a less homologous structural conformation in their binding grooves compared to BCL-2 and BCL-XL. Consequently, ABT-737 exhibits very low affinity for MCL-1 and BCL2A1, rendering it ineffective at inhibiting these specific survival proteins [2][3].
5. Current Limitations
Despite its potent senolytic and anti-tumor properties, the clinical utility of ABT-737 is severely restricted by two primary limitations. First, ABT-737 is not orally bioavailable, which complicates its administration and limits its use in chronic therapeutic regimens [3][8]. Second, ABT-737 induces dose-limiting, on-target toxicity in the form of severe thrombocytopenia. Platelet survival is critically dependent on BCL-XL; thus, the potent inhibition of BCL-XL by ABT-737 triggers rapid platelet apoptosis, leading to a dangerous depletion of blood platelets [4][5][8].
Additionally, therapeutic resistance to ABT-737 frequently emerges in cells that express high levels of MCL-1. Because ABT-737 cannot neutralize MCL-1, this protein acts as a compensatory survival factor, sequestering the pro-apoptotic proteins displaced from BCL-2 and BCL-XL and thereby preventing apoptosis [2][3].
6. Future Perspectives
To overcome the pharmacokinetic limitations of ABT-737, an orally bioavailable analog named ABT-263 (Navitoclax) was developed, which shares a similar target profile but remains limited by BCL-XL-mediated thrombocytopenia [3][8]. To circumvent platelet toxicity, subsequent drug design efforts yielded ABT-199 (Venetoclax), a highly selective BCL-2 inhibitor that spares BCL-XL and avoids thrombocytopenia, which has since achieved clinical approval for hematological malignancies [3][8][10].
In the context of senolytics, future research is focused on developing targeted delivery systems (such as proteolysis-targeting chimeras or galactose-conjugation) to direct BH3-mimetics specifically to senescent cells, thereby minimizing systemic toxicities [1]. Furthermore, combination therapies are being actively explored to overcome MCL-1-mediated resistance. Combining ABT-737 or its analogs with MCL-1 inhibitors, PI3K/AKT inhibitors, or standard chemotherapeutics has shown synergistic effects in inducing apoptosis in resistant tumor and senescent cell populations [3][4]. Continued investigation into the BCL-2 family dependencies of specific senescent cell types will pave the way for safer, more effective senolytic interventions for age-related diseases.
